Systematic Review and Meta-Analysis: Placebo Response in Randomized Controlled Trials of Tourette Disorder Medications

Pedro Macul Ferreira de Barros,Luis C. Farhat,Emily Behling,Madeeha Nasir,Angeli Landeros-Weisenberger,Michael H. Bloch

DOI: https://doi.org/10.1016/j.jaac.2024.10.011

IF: 13.113

2024-11-06

Journal of the American Academy of Child & Adolescent Psychiatry

Abstract:Objective To examine the magnitude of placebo response in randomized controlled trials (RCTs) of medications for Tourette disorder (TD). Method We searched CENTRAL, Embase, PubMed, PsycInfo, Web of Science, WHO ICTRP and ClinicalTrials.gov to identify placebo-controlled RCTs assessing pharmacological interventions for TD. Standardized mean change (SMC) and standardized mean difference were calculated for within-group (placebo, drug) and between-group (drug-placebo) change in tics. Data were pooled in random-effects meta-analysis. Meta-regressions were performed to identify study-level characteristics that could be differentially associated with placebo, drug, and drug-placebo response. Results We identified 13,775 records and included 50 RCTs involving 1,566 participants in the placebo meta-analysis. Placebo response was medium-to-large (SMC -0.62; 95% confidence interval [CI] -0.75 to -0.5; I 2 76%; τ 2 0.14). There were several factors associated with larger placebo responses (e.g., non-US RCT; industry sponsorship; number of centers and participants). However, there was a moderate-to-high correlation between placebo and drug response (ρ 0.66, 95% CI 0.47, 0.79), and factors associated with larger placebo response were also generally associated with larger drug responses. Also, there was not a significant correlation between placebo response and drug-placebo differences (ρ -0.05, 95% CI -0.32, 0.22), and factors associated with larger placebo response generally did not interfere in drug-placebo differences. Conclusion The magnitude of placebo response in TD may be large, but similar to that in other child psychiatry conditions. Clinical-researchers may manipulate study-level factors to diminish placebo response (for example, carefully selecting study sites and keeping them at the minimum feasibility). However, drug-placebo differences may not increase since drug response will likely diminish as well.

pediatrics,psychiatry,psychology, developmental